Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study

Table 4 Head-to-head comparison of patients who continued treatment with angiotensin receptor blockers with patients who continued treatment with angiotensin-converting enzyme inhibitors

Outcome	ARBs continued N=125		ACEIs continued N=136		Crude HR (95%CI)	PS-adj HR* (95%CI)	MC-HR** (95%CI)
Outcome	Patients with event	Event rate (%)	Patients with event	Event rate (%)	Crude HR (95%CI)	PS-adj HR* (95%CI)	MC-HR** (95%CI)
Death	26	20.8	45	33.1	0.57 (0.35–0.93)	0.56 (0.32–0.99)	0.52 (0.29–0.93)
Death + ICU	32	25.6	48	35.3	0.69 (0.44–1.08)	0.69 (0.41–1.16)	0.59 (0.35–1.01)

Abbreviations: ACEIs angiotensin-converting enzyme inhibitors, ARBs angiotensin receptor blockers, CI confidence interval, HR hazard ratio, ICU intensive care unit
*Propensity-scores-adjusted hazard ratio (adjusted total effect)
**Mediator-controlled hazard ratio (controlled direct effect): (a) systemic corticosteroids, anticoagulants, and immunomodulators when the outcome was death and (b) immunomodulators and anticoagulants when the outcome was death plus ICU admission

ISSN: 1741-7015